Nearly twenty years ago, Dr. Marc Hedrick at Cytori Therapeutics predicted that in years to come humans would someday donate their adult stem cells from fat tissue the way blood was, and is, donated today in order to cure diseases.Fast forward to 2019 and Dr. Jeffrey Gimble, CEO of LaCell is doing just that and more.
John Hartner, CEO of Dimension Inx, sees smoother regulatory pathways as essential to the near term availability of surgically friendly tissue for grafts.
“Collaboration is going to be the key factor for this new industry in biofabrication,” said Eric Gatenholm, co-founder and CEO of CELLINK, which quickly rose to IPO in under one year.
“Histogenics is a microcosm of ARMI/BioFabUSA in the regenerative medicine area of cartilage and musculoskeletal tissues,” said Steve Kennedy, Chief Operating Officer. “Our platform includes the process, manufacturing, regulatory, QC and clinical supplies for our industry,” he continued.
Michael Golway, CEO of Kentucky-based Advanced Solutions, is so committed to the mission of someday manufacturing human organs that he is moving dozens of staff from Kentucky to New Hampshire by the end of the 1st quarter in 2018.